Affiliation:
1. The S. Fyodorov Eye Microsurgery Federal State Institution
2. South Ural State Medical University
Abstract
Objective. To assess tolerability and the time of onset of clinical effect of dual-action antihistamine agents — Epinepta® (epinastine 0.05 %) and olopatadine 0.1 % in patients with seasonal allergic conjunctivitis (SAC).Subjects and methods. This was a prospective multicenter observational study. One hundred fifty patients with SAC (n = 150) were included into the study and divided into two groups (n = 75) in each. Patients in group 1 received epinastine 0.05 %, while patients into group 2 received olopatadine 0.1 %. Evaluation of clinical symptoms severity was performed using itching scale, hyperemia Efrone scale, eyelid swelling scale, lacrimation P. Munk scale, Shirmer test and Norn probe. Patients and healthcare providers satisfaction rate was assessed by Likert scale, patients self-control diary that helped to assess dry eye severity symptoms. Treatment period lasted 14 days.Results. Seasonal allergic conjunctivitis treatment with epinastine 0.05 % or olopatadine 0.1 % was equally effective. However epinastine 0.05 % was causing dry eye symptoms in lesser degree than olopatadine 0.1 %. These results refer to all parameters assessed by patients’ self-control diary — itching, discomfort, burning, eye blockage feeling.Conclusion. The study evaluated epinastine 0.05 % advantages compared to olopatadine 0.1 % in tear film preservation and causing less pronounced symptoms of dry eye in patients with acute seasonal allergic conjunctivitis. Monotherapy of seasonal allergic conjunctivitis with epinastine 0.05 % demonstrated high efficacy and lead to SAC clinical manifestations regress. Epinastine 0.05 % is recommended as a first line treatment of SAC.
Publisher
PE Polunina Elizareta Gennadievna
Reference18 articles.
1. Maichuk YuF. Seasonal pollen‑induced allergic conjunctivitis as the most common form of eye allergy. Part 1: epidemiology, aetiology, pathophysiology, clinical symptoms and diagnostics. Russian Ophthalmological Journal. 2010;3(1):37–41 (In Russ.).
2. Maichuk YuF. Allergic eye diseases. Moscow: Medicine, 1983. 224 p. (In Russ.).
3. Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol. 2011 Feb;106(2 Suppl):S2–5. doi: 10.1016/j.anai.2010.08.005.
4. Villegas BV, Benitez‑Del‑Castillo JM. Current Knowledge in Allergic Conjunctivitis. Turk J Ophthalmol. 2021 Feb 25;51(1):45–54. doi: 10.4274/tjo.galenos.2020.11456.
5. Maychuk DYu. Modern opportunities of therapeutic treatment of allergic conjunctivitis. A review. Ophthalmology in Russia. 2014;11(2):19–26. (In Russ.). doi: 10.18008/1816‑5095‑2014‑2‑19‑26.